4,901 trials
Diabetes Mellitus, Non-Insulin-Dependent
Primary: Number of Participants Who Experienced at Least One Adverse Event (AE) — 2; 2; 2; 2 participants
Corneal Neovascularization
Primary: The Size and Extent of Corneal Neovascularization Will be Measured by Computerized Image Analysis of Corneal Photographs Taken Throughout the Study. — 27.9 percent…
Healthy
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) for Amoxicillin — 27.8; 28.3 h*ug/ml
Type 2 Diabetes Mellitus
Primary: Number of Participants Experiencing Adverse Events (AEs) On Study — 2; 3; 3; 2 participants
Adult T-Cell Leukemia and Lymphoma (ATL) · Adult Peripheral T-Cell Lymphoma (PTCL)
Primary: Incidence of Dose-Limiting Toxicities (DLTs) — 1 participants
Allergic Rhinitis (AR)
Primary: Initial Deposition of Radioactivity Within the Nasal Cavity as a Percent of Delivered Dose — 99.48; 86.28 percentage of radiolabeled
Type 2 Diabetes Mellitus
Primary: Area Under the Curve (AUC)(0-∞) for Oral Compressed Tablet (OCT) (Fasted) and Dry Filled Capsule (DFC) (Fasted) — 763.76; 776.41 nM*hr — p=>0.200
Cancer
Primary: Number of Participants Who Had Reactogenicity Events (REs) — 8; 9 participants
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Determine Maximum Tolerated Dose of BPU — 150 milligrams (mg)
Coronary Artery Disease
Primary: Change From Baseline in Maximum Platelet Aggregation (MPA) to 20 Micromolar (µM) Adenosine Diphosphate (ADP) at Day 12 (Period 1) — 75.00; 76.40; 47.00; 47.00 percent…
Healthy
Primary: Time to Reach Maximum Serum Drug Concentration (Tmax) Following a Single Dose of Belimumab Given as Intravenous Infusion (IV) or Subcutaneous Injection (SC) — 0.09; 3.9…
Healthy
Primary: AUC0-tz — 1970; 1950 ng*hour/mL
Oral Mucositis
Primary: Ratio to Baseline of Epithelial Cell Proliferation as Assessed by Ki67 Staining of Buccal Mucosal Tissue. — 0.267; 0.414 ratio
Opioid Analgesia
Primary: Single-dose PK Metric: Area Under the Plasma Concentration-time Curve From Hour 0 to the Last Measurable Plasma Concentration [AUCt] — 129.2; 121.1; 272.2; 85.5 ng*h/mL
Cystic Fibrosis
Primary: Change in Average Mucociliary Clearance (0-90 Minutes) at 1 and 4 Hrs Post Dose (MCC4hr - MCCbaseline; MCC1hr - MCCbaseline) — 5.9; 6.7 Absolute % change